Cadonilimab plus chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer: a cost-effectiveness analysis
In China, cadonilimab plus chemotherapy is not considered cost-effective compared to standard chemotherapy as a first-line treatment for the general p/r/m CC population. However, it represents a cost-effective option for patients ineligible for bevacizumab therapy.
Authors
- Zhengxiong Li (ORCID: https://orcid.org/0000-0003-1880-5096)
- Yingzhou Fu
- Xiaojuan Chen (ORCID: https://orcid.org/0000-0002-3372-6807)
- Zuojuan Xiang
Institutions
- Central South University (CN)
- Xuzhou Medical College (CN)
- Hunan Cancer Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-04-03
- DOI
- https://doi.org/10.3389/fimmu.2025.1562875
- Citations
- 5
- Primary Topic
- Colorectal and Anal Carcinomas
- Type
- article
- Field-Weighted Citation Impact
- 10.03